Multiplex ARMS analysis to detect 13 common mutation

Clinical Genetics

71, 561-568

DOI: 10.1111/j.1399-0004.2007.00807.x

Citation Report

#	Article	IF	Citations
1	PCSK9Â: un exemple de recherche translationnelle. Medecine Des Maladies Metaboliques, 2008, 2, 10-14.	0.1	0
2	Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. European Heart Journal, 2008, 29, 2625-2633.	2.2	391
3	Identifying patients with familial hypercholesterolaemia in primary care. Heart, 2008, 94, 695-696.	2.9	8
4	What is the clinical utility of DNA testing in patients with familial hypercholesterolaemia?. Current Opinion in Lipidology, 2008, 19, 362-368.	2.7	62
5	Identification of loci conferring risk for premature CAD and heterozygous familial hyperlipidemia in the LDLR, APOB and PCSK9 genes. International Journal of Diabetes Mellitus, 2009, 1, 16-21.	0.6	5
6	Evaluation of high-resolution melting analysis for screening the LDL receptor gene. Clinical Biochemistry, 2009, 42, 528-535.	1.9	18
7	Multiplex ligationâ€dependent probe amplification analysis to screen for deletions and duplications of the LDLR gene in patients with familial hypercholesterolaemia. Clinical Genetics, 2009, 76, 69-75.	2.0	29
8	Mutation screening in patients for familial hypercholesterolaemia (ADH). Clinical Genetics, 2010, 77, 97-99.	2.0	18
9	Mutation detection rate and spectrum in familial hypercholesterolaemia patients in the UK pilot cascade project. Clinical Genetics, 2010, 77, 572-580.	2.0	155
10	Genetic screening for homozygous and heterozygous familial hypercholesterolemia. The Application of Clinical Genetics, 2010, 3, 147.	3.0	5
11	A double heterozygote for familial hypercholesterolaemia and familial defective apolipoprotein B-100. Annals of Clinical Biochemistry, 2010, 47, 487-490.	1.6	16
12	Development of a high-resolution melting method for mutation detection in familial hypercholesterolaemia patients. Annals of Clinical Biochemistry, 2010, 47, 44-55.	1.6	38
13	Familial hypercholesterolemia: epidemiology, Neolithic origins and modern geographic distribution. Critical Reviews in Clinical Laboratory Sciences, 2011, 48, 1-18.	6.1	57
14	Familial hypercholesterolaemia: A model of care for Australasia. Atherosclerosis Supplements, 2011, 12, 221-263.	1.2	181
15	Mechanisms and genetic determinants regulating sterol absorption, circulating LDL levels, and sterol elimination: implications for classification and disease risk. Journal of Lipid Research, 2011, 52, 1885-1926.	4.2	76
16	A DNA Microarray for the Detection of Point Mutations andÂCopy Number Variation Causing Familial Hypercholesterolemia in Europe. Journal of Molecular Diagnostics, 2013, 15, 362-372.	2.8	17
17	The use of next-generation sequencing in clinical diagnosis of familial hypercholesterolemia. Genetics in Medicine, 2013, 15, 948-957.	2.4	69
18	Multiplex ARMS PCR to Detect 8 Common Mutations of ATP7B Gene in Patients With Wilson Disease. Hepatitis Monthly, 2013, 13, e8375.	0.2	6

#	Article	IF	Citations
19	Molecular characterization of a Chinese woman homozygous for the familial hypercholesterolemiaLDLRc.1474G>A (p.Asp492Asn) mutation. Clinical Lipidology, 2014, 9, 163-170.	0.4	1
20	Screening for Familial Hypercholesterolaemia: Universal or Cascade? A Critique of Current FH Recognition Strategies. Current Cardiovascular Risk Reports, 2015, 9, 1.	2.0	3
21	Mutation p.L799R in the LDLR, which affects the transmembrane domain of the LDLR, prevents membrane insertion and causes secretion of the mutant LDLR. Human Molecular Genetics, 2015, 24, 5836-5844.	2.9	15
22	Childâ€“Parent Familial Hypercholesterolemia Screening in Primary Care. New England Journal of Medicine, 2016, 375, 1628-1637.	27.0	250
23	PCSK9 Variants in Familial Hypercholesterolemia: A Comprehensive Synopsis. Frontiers in Genetics, 2020, 11, 1020.	2.3	29
24	Genetics of Cardiovascular Diseases. , 2009, , 281-293.		2
26	Elucigene FH20 and LIPOchip for the diagnosis of familial hypercholesterolaemia: a systematic review and economic evaluation.. Health Technology Assessment, 2012, 16, 1-266.	2.8	15
27	Prioritization of Candidate Nonsynonymous Single Nucleotide Polymorphisms via Sequence Conservation Features. International Journal of Engineering and Manufacturing, 2011, 1, 66-72.	0.7	1
28	Genetic testing for familial hypercholesterolemiaâ€”past, present, and future. Journal of Lipid Research, 2021, 62, 100139.	4.2	20
29	cSNP Identification and Genotyping from C4B and BAT2 Assigned to the SLA Class III Region. Journal of Animal Science and Technology, 2007, 49, 549-558.	2.5	0
30	Cloning, cSNP Identification, and Genotyping of Pig Complement Factor B(CFB) Gene Located on the SLA Class III Region. Journal of Animal Science and Technology, 2008, 50, 753-762.	2.5	0
31	Extraction of Sequence Conservation Features for the Prioritization of Candidate Single Amino Acid Polymorphisms. International Journal of Information Engineering and Electronic Business, 2011, 3, 1-10.	1.2	3
32	A 72-Year-Old Patient with Longstanding, Untreated Familial Hypercholesterolemia but no Coronary Artery Calcification: A Case Report. Cureus, 2018, 10, e2452.	0.5	1